Immunotherapy holds great promise in the treatment of Myasthenia Gravis (MG), unleashing the power of the immune system to combat the underlying autoimmune dysfunction. Targeted immunotherapeutic approaches aim to modulate the immune response and restore the balance between autoimmunity and tolerance. Intravenous immunoglobulin (IVIg) and plasma exchange are effective in providing temporary...
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian